Introduction {#sec1}
============

To obtain a definite diagnosis of chest pathology is not an easy task. Groups of pulmonary nodules, lung infiltrations, and other chest pathologies comprise a variety of malignant and benign lesions that are difficult to differentiate with use of radiological investigation \[[@cit0001]\].

In numerous studies investigators have evaluated the usefulness of transthoracic needle biopsy in the diagnostic work-up of lung parenchymal lesions \[[@cit0002]-[@cit0004]\], but only a few studies have elaborated this diagnostic tool for chest wall tumours, mediastinal masses, or pleural lesions \[[@cit0005]-[@cit0007]\]. Both fine-needle aspiration and core biopsy have high diagnostic accuracy with acceptable complication rates \[[@cit0008], [@cit0009]\]. The purpose of the study is to present the diagnostic accuracy, pathological findings, and risk of complications connected with the aspiration or core transthoracic needle biopsy in various chest pathologies.

Material and methods {#sec2}
====================

A total of 593 transthoracic biopsies were performed between April 2013 and August 2016 in our Radiology Department by the same radiologist. We present a retrospective analysis of the procedures.

All biopsies were performed computed tomography (CT)- or CT-fluoroscopy-guided and were performed using a 128-row CT scanner.

Fine-needle aspiration biopsy (FNAB) or core biopsy (CB) were performed.

Before the procedure, informed consent was obtained in all cases. A 1% solution of lidocaine was used as local anaesthesia.

All performed procedures were divided into four groups according to the location of the pathology:

-   lung lesions (LL) -- 540 procedures: all intraparenchymal lesions with probable lung parenchyma origin (including lung lesions infiltrating the mediastinum, pleura, or chest wall), subdivided into:

    -   --lung tumours: well-defined nodules with sharp, definite margins separating them from healthy lung parenchyma,

    -   --lung infiltration: ill-defined lesions without sharp borders, which infiltrate lung parenchyma;

-   mediastinum masses (MM) -- 25 procedures: both mass or lymph nodes located originally in the mediastinum (bone or pleural lesions with mediastinal involvement were excluded from this group);

-   chest wall tumours (CWT) -- 13 procedures: masses with probable origin within chest wall structures such as ribs and muscles (lung tumours with chest wall involvement were excluded from this group);

-   pleural lesions (PL) -- 15 procedures: pathologies located within or between parietal and visceral pleura (lung tumours with pleural infiltration were excluded from this group).

Examples of lesions from separate groups are presented in [Figures 1](#f0001){ref-type="fig"}-[5](#f0005){ref-type="fig"}. For each group specific information such as pathological outcomes, sensitivity, and complication rate is provided.

![An example of lung tumour biopsy -- typical carcinoid was confirmed](PJR-83-32801-g001){#f0001}

![An example of lung infiltration biopsy -- pulmonary adenocarcinoma was confirmed](PJR-83-32801-g002){#f0002}

![An example of mediastinal mass biopsy in a male patient -- primary mediastinal choriocarcinoma was confirmed](PJR-83-32801-g003){#f0003}

![An example of chest wall tumour biopsy -- Ewing sarcoma was confirmed](PJR-83-32801-g004){#f0004}

![An example of pleural lesion biopsy -- pathological evaluation confirmed mesothelioma](PJR-83-32801-g005){#f0005}

As regards complications, we noted that all (even the smallest) areas of pneumothorax were visualised in the follow-up X-ray the next day after the procedure. Also, we analysed the pneumothorax in respect of whether chest tube insertion was needed or not. Pneumothorax requiring chest drainage was defined as any symptomatic pneumothorax (pain and/or dyspnoea) or pneumothorax surrounding the entire lung on plain PA chest X-ray. The decision was undertaken by a board-certified thoracic surgeon.

We also noted any alveolar haemorrhages that appeared in follow-up CT scan both with or without further haemoptysis. We recorded all cases of blood spitting observed after the procedure, including minor spitting without the need for drug administration.

For statistical analysis, raw numbers and percentage values were used for descriptive data. Fisher's exact and Wilcoxon tests were used for a comparable analysis of separate groups.

Sensitivity for malignancy detection was calculated.

The result was considered true positive when a malignancy revealed after FNAB or CB was confirmed by surgical resection or other diagnostic procedure such as endobronchial ultrasound-guided biopsy (EBUS), bronchofiberoscopy, or thoracoscopy, or when the pathological result was sufficient for further treatment. The result was considered false negative when biopsy revealed no malignancy, but after surgery or other diagnostic procedure the neoplastic character of the tumour was confirmed.

Negative cases without any further diagnostic work-up or CT control were excluded from the sensitivity calculations.

Results {#sec3}
=======

Biopsy details {#sec3.1}
--------------

The average size of punctured lung nodules was 27 mm and lung infiltration was 41 mm (*p* \< 0.01). In the case of lung tumours, both CB and FNAB were performed with comparable frequency rate (214 FNAB vs. 292 CB), but in the lung infiltration group core biopsy was the preferred technique (32 CB vs. 2 FNAB, *p* \< 0.01).

The mean size of mediastinal tumours was 55 mm and chest wall tumours 44 mm. We did not measure the size of pleural lesions because most of them were widely spread in the entire pleura. Core biopsy was the preferred diagnostic technique in all three groups (MM -- 84%, CWT and PL -- 100%). CT fluoroscopy during core biopsy was widely used in the MM group (in 85% of procedures) but only occasionally in the CWT and PL groups (20-27% of procedures).

For the CB procedures of lung tumours an 18-gauge needle was used most commonly, but in other groups of lesions higher gauge needles were selected.

Biopsy details are summarised in [Table 1](#t0001){ref-type="table"}.

###### 

Biopsy details for various groups of pathologies

                          Lung tumours   506     Lung infiltration   34      Mediastinal masses   25      Chest wall tumours   13      Pleural lesions   15
  ----------------------- -------------- ------- ------------------- ------- -------------------- ------- -------------------- ------- ----------------- ------
  Size (mm)               27.2                                       41.2                         55.2                         44.3                      
  Biopsy details                                                                                                                                         
  FNAB (22-gauge)         214            42.3%   2                   5.9%    4                    16%     0                    0%      0                 0%
  Use of CT fluoroscopy   4              1.9%    0                   0%      2                    50%                                                    
  CB                      292            57.7%   32                  94.1%   21                   84%     13                   100%    15                100%
   12-gauge               4              1.3%    1                   3.1%    0                    0%      3                    23%     2                 13%
   14-gauge               48             16.5%   9                   28.1%   1                    4.8%    7                    53.8%   4                 27%
   16-gauge               87             29.9%   16                  50%     15                   71.4%   2                    15.4%   6                 40%
   18-gauge               149            51%     6                   18.8%   5                    23.8%   1                    7.7%    3                 20%
   20-gauge               4              1.3%    0                   0%      0                    0%      0                    0%      0                 0%
  Use of CT fluoroscopy   165            60.8%   0                   0%      18                   85.7%   3                    23%     3                 20%

FNAB -- fine-needle aspiration biopsy, CT -- computed tomography, CB -- core biopsy

Diagnostic accuracy and pathological outcomes {#sec3.2}
---------------------------------------------

Specific pathological diagnosis was confirmed in 447 cases after all 593 procedures. Sensitivity of malignancy diagnosis in the group of lung tumours was 75% for FNAB and 89.1% for CB. Sensitivity in other groups, where CB was also the most preferred technique, was counted, respectively, for lung infiltration, mediastinal masses, chest wall tumours, and pleural lesions as 83.3%, 90.9%, 100%, and 85.7%.

In the group of lung tumours malignancy was confirmed most commonly (79%), but in the lung infiltration group benign process was revealed more frequently (83%). In the MM and CWT group malignant neoplasm dominated in pathological analysis, but among pleural lesions the rate of malignant and benign processes was comparable.

The most common malignancy in the lung tumour group was adenocarcinoma (135 of 295; 46%). Among benign nodular lesions, acute or chronic inflammatory process was the most common finding (43 of 76; 57%). Interstitial diseases and inflammatory processes were most commonly confirmed in the lung infiltration group (20 of 34; 59%). Small cell carcinoma and lymphoma dominated among mediastinal pathologies. Metastatic character of chest wall tumours was proven in 88% cases. In pleural lesions the rate of metastases and benign, fibrotic changes was comparable.

Detailed information about diagnostic accuracy and pathological results is presented in [Table 2](#t0002){ref-type="table"} and [Table 3](#t0003){ref-type="table"}.

###### 

Diagnostic accuracy calculated for all groups of pathologies

                                Lung tumours   Lung infiltration   Mediastinal masses   Chest wall tumours   Pleurallesions   
  ----------------------------- -------------- ------------------- -------------------- -------------------- ---------------- ------------
  Number of procedures          214            292                 34                   25                   13               15
  Diagnosis obtained            131 (61.2%)    241 (82.5%)         30 (88.2%)           21 (84.0%)           13 (100.0%)      11 (73.3%)
  Malignant                     115 (53.7%)    180 (61.6%)         5 (14.7%)            20 (80.0%)           8 (61.5%)        6 (40.0%)
  Benign                        16 (7.5%)      60 (20.5%)          25 (3.5%)            1 (4.0%)             5 (38.5%)        5 (33.3%)
  No diagnosis                  83 (38.8%)     52 (17.8%)          4 (11.8%)            4 (16.0%)            0 (0.0%)         4 (26.7%)
  TP                            114            180                 5                    20                   8                6
  TN                            37             55                  21                   2                    3                5
  Sensitivity                   75.0%          89.1%               83.3%                90.9%                100.0%           85.7%
  Not included in calculation   25 (11.7%)     35 (10.8%)          7 (20.6%)            1 (4.0%)             2 (15.4%)        3 (20.0%)

FNAB -- fine-needle aspiration biopsy, CB -- core biopsy, TP -- xxxxxx, TN -- xxxxxxx

###### 

Specification of pathological findings in all groups of chest pathologies

  Pathological findings               Lung tumours   Lung infiltration   Mediastinal masses   Chest walltumours   Pleurallesions   
  ----------------------------------- -------------- ------------------- -------------------- ------------------- ---------------- ------------
  **Malignant**                       **115**        **180**             **5**                **20**              **8**            **6**
  Non-specified NSCLC                 12 (10.4%)     11 (6.1%)           0 (0.0%)             1 (5.0%)            0 (0.0%)         0 (0.0%)
  Adenocarcinoma                      59 (51.3%)     76 (42.2%)          3 (60.0%)            0 (0.0%)            0 (0.0%)         0 (0.0%)
  Carcinoma planoepitheliale          18 (15.7%)     43 (23.9%)          0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
  Neuroendocrine NSCLC                3 (2.6%)       7 (3.8%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
  SCLC                                9 (7.8%)       4 (2.2%)            0 (0.0%)             6 (30.0%)           0 (0.0%)         0 (0.0%)
  Combined NSCLC + SCLC               5 (4.3%)       3 (1.6%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
  Mesothelioma malignum               0 (0.0%)       0 (0.0%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         1 (16.7%)
  Metastases                          9 (7.8%)       30 (16.6%)          2 (40.0%)            3 (15.0%)           7 (87.5%)        5 (83.3%)
  Others                              0 (0.0%)       6 (3.3%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
   Sarcoma                            0 (0.0%)       3 (1.9%)            0 (0.0%)             2 (10.0%)           1 (12.5%)        0 (0.0%)
   Thymic cancer                      0 (0.0%)       0 (0.0%)            0 (0.0%)             1 (5.0%)            0 (0.0%)         0 (0.0%)
   Choriocarcinoma                    0 (0.0%)       0 (0.0%)            0 (0.0%)             1 (5.0%)            0 (0.0%)         0 (0.0%)
   Lymphoma                           0 (0.0%)       3 (0.6%)            0 (0.0%)             6 (30.0%)           0 (0.0%)         0 (0.0%)
  **Benign**                          **16**         **60**              **25**               **1**               **5**            **5**
  Sarcoidosis                         0 (0.0%)       5 (8.3%)            2 (8.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
  Tuberculosis                        2 (12.5%)      6 (10%)             3 (12.0%)            0 (0.0%)            0 (0.0%)         0 (0.0%)
  Inflammatory process                6 (37.5%)      37 (61.7%)          10 (40.0%)           1 (100.0%)          3 (60.0%)        0 (0.0%)
  Interstitial disease                0 (0.0%)       3 (5%)              10 (40.0%)           0 (0.0%)            0 (0.0%)         0 (0.0%)
  Granulomatosis with polyangiitis    0 (0.0%)       3 (5%)              0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
  Others                              8 (50.0%)      6 (10%)             0 (0.0%)             0 (0.0%)            2 (40.0%)        5 (100.0%)
   Neurofibroma                       0 (0.0%)       2 (3.8%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
   Hamartoma                          6 (37.5%)      0 (0.0%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
   Fibrotic pleural lesions           0 (0.0%)       1 (1.9%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         5 (100.0%)
   Pneumoconiosis                     2 (12.5%)      0 (0.0%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
   Rheumatoid nodule                  0 (0.0%)       0 (0.0%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)
   Atypical adenomatous hyperplasia   0 (0.0%)       3 (1.9%)            0 (0.0%)             0 (0.0%)            0 (0.0%)         0 (0.0%)

NSCLC -- non-small cell lung carcer, SCLC -- small cell lung cancer

Complications {#sec3.3}
-------------

In the group of lung tumours pneumothorax was revealed on follow-up X-ray in 71 of 214 (33.2%) FNABs and 89 of 292 (30.5%) CBs, and there was no statistical difference between these two techniques (*p* = 0.2).

The frequency of chest tube insertion due to pneumothorax was also comparable for each of the techniques (*p* = 0.9) and amounted to 14% for FNAB and 12.3% for CB. The frequency of drainage in the lung infiltration group after CB was 12.5%, and it was the same as in the lung tumour group (*p* = 0.7).

The pneumothorax rate in the mediastinal masses group was 23.8%, but drainage was necessary in one case only. In the other two groups pneumothorax was observed occasionally, and it never required further intervention.

Alveolar haemorrhage was commonly seen after procedures performed due to lung tumour and lung infiltration, and definitely more frequently when core needle was used (*p* \< 0.01). Moreover, haemoptysis also was often seen after CB, but only occasionally after FNAB (12.3% in CB vs. 1.4% in FNAB, *p* \< 0.01). There was no revealed haemoptysis after procedures performed due to mediastinal mass, chest wall tumour, or pleural lesion.

Complications are listed in [Table 4](#t0004){ref-type="table"}.

###### 

Complication after biopsy procedure reported in each group of chest pathologies

  Complications                               Lung tumours   Lung infiltration   Mediastinal masses   Chest wall tumours   Pleural lesions                                                              
  ------------------------------------------- -------------- ------------------- -------------------- -------------------- ----------------- ------- ---- ------- --- ------ --- ------- --- ------ --- ------
  Pneumothorax                                71             33.2%               89                   30.5%                1                 50.0%   8    25.0%   0   0.0%   5   23.8%   0   0.0%   1   8.3%
  Pneumothorax without chest tube insertion   41             19.2%               53                   18.2%                1                 50.0%   4    12.5%   0   0.0%   4   19.0%   0   0.0%   1   8.3%
  Pneumothorax with chest tube insertion      30             14.0%               36                   12.3%                0                 0.0%    4    12.5%   0   0.0%   1   4.8%    0   0.0%   0   0.0%
  Alveolar haemorrhage                        62             29.0%               113                  38.7 %               0                 0.0%    10   31.3%   0   0.0%   2   9.5%    0   0.0%   0   0.0%
  Haemoptysis                                 3              1.4%                36                   12.3%                0                 0.0%    4    12.5%   0   0.0%   0   0.0%    0   0.0%   0   0.0%
  Pleural haematoma                           3              1.4%                4                    1.4%                 0                 0.0%    0    0.0%    0   0.0%   0   0.0%    0   0.0%   0   0.0%

NAB -- fine-needle aspiration biopsy, CB -- core biopsy

Discussion and conclusions {#sec4}
==========================

In chest radiology, behind the large variety of radiological outcomes stands an even greater number of pathological diagnoses. For further treatment it is crucial to differentiate malignant neoplasms from benign processes. In daily practice of many institutions CT-guided percutaneous needle biopsy is still the gold standard of evaluation of chest pathologies \[[@cit0005], [@cit0007], [@cit0008], [@cit0010]\].

In this study we presented our experience in CT-guided needle biopsies performed due to chest pathologies. In our material we found several significant issues:

1.  Core biopsy is a more sensitive technique in lung malignancy detection than fine-needle aspiration biopsy.

2.  Core biopsy is a highly accurate technique for evaluation other chest pathologies such as mediastinal masses, chest wall tumours, or pleural lesions.

3.  There is no statistical difference between pneumothorax rate and pneumothorax requiring drainage after CB and FNAB.

4.  Haemoptysis was observed more commonly after CB than after FNAB.

In a meta-analysis Zhang *et al*. reported that the sensitivity for FNAB varied between 68% and 95%, and between 84% and 97% for CB \[[@cit0008]\]. A comparison of our results with those from Zhang *et al*. shows that we obtained similar sensitivity for FNAB and CB in evaluation of lung tumours. We also observed that CT-guided core biopsy is an effective and very safe procedure in the diagnostic field of other chest pathologies \[[@cit0009]\]. Other authors also recommended it as the procedure of first choice in the evaluation of mediastinal masses \[[@cit0006]\], chest wall tumours \[[@cit0007]\], and pleural lesions \[[@cit0005]\], obviating more invasive procedures such as thoracoscopy, mediastinoscopy, or thoracotomy.

Heering *et al*. analysed numerous previous studies according to complication rate, and noted that the pneumothorax rate and pneumothorax with intervention varied greatly (8-50% and 0-19%, respectively) \[[@cit0009]\]. According to their analysis, the pneumothorax rate is strongly connected with the size of the needle, and its rate is higher after CB procedures. Conversely, the pneumothorax and pneumothorax with intervention rate in our study was similar in each technique used. However, as in the above-mentioned meta-analysis, we found that a thicker needle increased the risk of haemoptysis \[[@cit0009]\].

Conclusions {#sec5}
===========

Both FNAB and CB are useful, safe, and sensitive tools, which can be used in chest pathology diagnostic work-up, with acceptably low risk of complications.
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